登革热防治研究进展

李晋涛

doi:10.16016/j.1000-5404.201909095

您当前的位置：

首页 >

文章列表页 >

登革热防治研究进展

专家述评 | 更新时间：2026-01-09

- 登革热防治研究进展
- Advances in prevention and control for dengue fever
- 第三军医大学学报 2019年41卷第19期页码：1902-1907
- 作者机构：
  
  400038 重庆，陆军军医大学(第三军医大学)基础医学院军事生物安全教研室
- 作者简介：
  
  [李晋涛，博士，教授，博士生导师。担任中国人兽共患病学术委员会委员，重庆市免疫学会理事，国家重大专项评委，首届军队生物安全智库专家组成员等职务。先后主持国家科技支撑计划、国家自然科学基金面上项目等课题20余项。获国家发明专利授权18项，国际PCT专利1项。在SCI收录期刊上发表论文42篇，军队育才银奖获得者。主要从事病原感染与防御策略方面的研究。E-mail: ljtqms@qq.comLI Jintao, E-mail: ljtqms@qq.com
- 基金信息：
  
  国家自然科学基金面上项目(81570497)
- DOI：10.16016/j.1000-5404.201909095
  中图分类号： R512.8
- 收稿：2019-09-12，
  
  修回：2019-09-18，
  
  纸质出版：2019-10-15
- 稿件说明：
移动端阅览
李晋涛. 登革热防治研究进展[J]. 第三军医大学学报, 2019,41(19):1902-1907.

Jintao LI. Advances in prevention and control for dengue fever[J]. Journal of Third Military Medical University, 2019, 41(19): 1902-1907.
李晋涛. 登革热防治研究进展[J]. 第三军医大学学报, 2019,41(19):1902-1907. DOI： 10.16016/j.1000-5404.201909095.

Jintao LI. Advances in prevention and control for dengue fever[J]. Journal of Third Military Medical University, 2019, 41(19): 1902-1907. DOI： 10.16016/j.1000-5404.201909095.

摘要

登革热(dengue fever)是一种由携带登革病毒(dengue virus)的蚊媒叮咬引起的急性传染性疾病。登革热已经在100多个国家和地区流行，每年约有3.9亿人感染。2019年初世界卫生组织(WHO)将登革病毒引起的登革热疾病列为2019年全球健康面临的十大威胁之一。自2019年年初至8月底，登革热疫情已在全球20多个国家和地区暴发，感染人数超过150万例。登革热发病机制尚不明确，且迄今没有特效药，疫苗预防和蚊媒控制是遏制登革病毒传播的有效手段。本文阐述近年来登革疫苗的研发和蚊媒控制方面的最新进展，提出未来登革疫苗发展有望在优势抗原重新组合、开发新型递送系统等方面获得突破，基因编辑等新型技术的兴起可促进蚊媒控制研究的发展。

Abstract

Dengue fever is an acute infectious disease caused by mosquito vector bites carrying dengue virus. Dengue fever has been prevalent in more than 100 countries and regions

with about 390 million people infected each year. In early 2019

the World Health Organization (WHO) listed dengue fever caused by dengue virus as one of the top 10 threats to global health in 2019. From the beginning of 2019 to the end of August

dengue fever outbreaks have occurred in more than 20 countries and regions around the world

with more than 1.5 million cases of infection. Up to date

it is not clear about the pathogenesis of dengue fever

and there is no target drug. Vaccine prevention and mosquito vector control are effective means to control the transmission of the virus. Vaccine prevention and mosquito vector control are effective means to curb the spread of dengue virus. This article reviews the latest progress in the research and development of dengue vaccine and mosquito vector control in recent years. The development of dengue vaccine in the future is expected to make breakthroughs in the reassembly of dominant antigens and the development of new delivery systems. The rise of new technologies such as gene editing will promote the development of mosquito vector control research.

关键词

Keywords

references

[World Healthy Organization. Dengue control[EB/OL ] . https://www.who.int/denguecontrol/disease/en/ https://www.who.int/denguecontrol/disease/en/ .

[MARIMUTHU P, RAVINDER J R. Trends in clinical trials of dengue vaccine[J ] . Perspect Clin Res, 2016, 7(4): 161-164. DOI: 10.4103/2229-3485.192035. http://outbreaks.globalincidentmap.com/ http://outbreaks.globalincidentmap.com/ .

TORRESI J, EBERT G, PELLEGRINI M. Vaccines licensed and in clinical trials for the prevention of dengue[J]. Hum Vaccin Immunother, 2017, 13(5): 1059-1072. DOI:10.1080/21645515.2016.1261770.

[Dutbreaks: Displaying outbreaks, case and deaths from viral and bacterial diseases which have the potential to indicate biological terrorism[EB/OL ] . http://outbreaks.globalincidentmap.com/ http://outbreaks.globalincidentmap.com/ .

MARTÍNEZ-VEGA R A, CARRASQUILA G, LUNA E, et al . ADE and dengue vaccination[J ] . Vaccine, 2017, 35(32):3910-3912. DOI: 10.1016/j.vaccine.2017.06.004.

SLON-CAMPOS J L, DEJNIRATTISAI W, JAGGER B W, et al . A protective Zika virus E-dimer-based subunit vaccine engineered to abrogate antibody-dependent enhancement of dengue infection[J ] . Nat Immunol. 2019. [Epub ahead of print ] . DOI:10.1038/s41590-019-0477-z.

DORIGATTI I, DONNELLY C A, LAYDON D J, et al . Refined efficacy estimates of the Sanofi Pasteur dengue vaccine CYD-TDV using machine learning[J ] . Nat Commun, 2018, 9(1): 3644. DOI:10.1038/s41467-018-06006-6.

PAESSLER S, WALKER D H. Pathogenesis of the viral hemorrhagic fevers[J]. Annu Rev Pathol, 2013, 8: 411-440. DOI:10.1146/annurev-pathol-020712-164041.

PROMPETCHARA E, KETLOY C, THOMAS S J, et al . Dengue vaccine: global development update[J ] . Asian Pac J Allergy Immunol, 2019.[Epub ahead of print ] . DOI: 10.12932/AP-100518-0309.

KAO Y S, YU C Y, HUANG H J, et al . Combination of modified NS1 and NS3 as a novel vaccine strategy against dengue virus infection[J ] . J Immunol, 2019.[Epub ahead of print ] . DOI: 10.4049/jimmunol.1900136.

LI L K, MENG W X, HORTON M, et al . Potent neutralizing antibodies elicited by dengue vaccine in rhesus macaque target diverse epitopes[J ] . PLoS Pathog, 2019, 15(6): e1007716. DOI:10.1371/journal.ppat.1007716.

ROTH C, CANTAERT T, COLAS C, et al . A modified mRNA vaccine targeting immunodominant NS epitopes protects against dengue virus infection in HLA class I transgenic mice[J ] . Front Immunol, 2019, 10: 1424. DOI:10.3389/fimmu.2019.01424.

WA NG R, GAO N, LI Y, et al . Cross-protection against four serotypes of dengue virus in mice conferred by a zika DNA vaccine[J ] . Front Cell Infect Microbiol, 2019, 9: 147. DOI:10.3389/fcimb.2019.00147.

FERNANDEZ S, THOMAS S J, DE LA BARRERA R, et al . An adjuvanted, tetravalent dengue virus purified inactivated vaccine candidate induces long-lasting and protective antibody responses against dengue challenge in rhesus macaques[J ] . Am J Trop Med Hyg, 2015, 92(4): 698-708. DOI:10.4269/ajtmh.14-0268.

WILDER-SMITH A, HOMBACH J, FERGUSON N, et al . Deliberations of the strategic advisory group of experts on immunization on the use of CYD-TDV dengue vaccine[J ] . Lancet Infect Dis, 2019, 19(1): e31-e38. DOI:10.1016/S1473-3099(18)30494-8.

TORRESI J, EBERT G, PELLEGRINI M. Vaccines licensed and in clinical trials for the prevention of dengue[J]. Hum Vaccin Immunother, 2017, 13(5): 1059-1072. DOI:10.1080/21645515.2016.1261770.

DYER O. Philippines to charge Sanofi staff and government officials over dengue vaccine[J]. BMJ, 2019, 364: l1088. DOI:10.1136/bmj.l1088.

COHEN J. Controversy over dengue vaccine risk[J]. Science, 2019, 365(6457): 961-962. DOI:10.1126/science.365.6457.961.

SRIDHAR S, LUEDTKE A, LANGEVIN E, et al . Effect of dengue serostatus on dengue vaccine safety and efficacy[J ] . N Engl J Med, 2018, 379(4): 327-340. DOI:10.1056/NEJMoa1800820.

VOELKER R. Dengue vaccine gets the nod[J]. JAMA, 2019, 321(21): 2066. DOI:10.1001/jama.2019.6886.

DA SILVEIRA L T C, TURA B, SANTOS M. Systematic review of dengue vaccine efficacy[J]. BMC Infect Dis, 2019, 19(1): 750. DOI:10.1186/s12879-019-4369-5.

TORRES J R, FALLEIROS-ARLANT L H, GESSNER B D, et al . Updated recommendations of the international dengue initiative expert group for CYD-TDV vaccine implementation in Latin America[J ] . Vaccine, 2019. [Epub ahead of print ] . DOI:10.1016/j.vaccine.2019.09.010.

LUO R, FONGWEN N, KELLY-CIRINO C, et al . Rapid diagnostic tests for determining dengue serostatus: a systematic review and key informant interviews[J ] . Clin Microbiol Infect, 2019, 25(6): 659-666. DOI:10.1016/j.cmi. 2019.01.002.

POPPER S J, STROUTS F R, LINDOW J C, et al . Early transcriptional responses after dengue vaccination mirror the response to natural infection and predict neutralizing antibody titers[J ] . J Infect Dis, 2018, 218(12): 1911-1921. DOI:10.1093/infdis/jiy434.

WHITEHEAD S S. Development of TV003/TV005, a single dose, highly immunogenic live attenuated dengue vaccine; what makes this vaccine different from the Sanofi-Pasteur CYD TM vaccine?[J ] . Expert Rev Vaccines, 2016;15(4):509-517. DOI:10.1586/14760584.2016.1115727.

SÁEZ-LLORENS X, TRICOU V, YU D L, et al . Immunogenicity and safety of one versus two doses of tetravalent dengue vaccine in healthy children aged 2-17 years in Asia and Latin America: 18-month interim data from a phase 2, randomised, placebo-controlled study[J ] . Lancet Infect Dis, 2018, 18(2):162-170. DOI: 10.1016/S1473-3099(17)30632-1.

SHAW W R, CATTERUCCIA F. Vector biology meets disease control: using basic research to fight vector-borne diseases[J]. Nat Microbiol, 2019, 4(1):20-34. DOI: 10.1038/s41564-018-0214-7.

ARMBRUSTER P A. Tiger mosquitoes tackled in a trial[J]. Nature, 2019, 572(7767): 39-40. DOI:10.1038/d41586-019-02000-0.

O'NEILL S L, RYAN P A, TURLEY A P, et al . Scaled deployment of Wolbachia to protect the community from dengue and other Aedes transmitted arboviruses[J ] . Gates Open Res, 2018, 2: 36. DOI:10.12688/gatesopenres.12844.2.

O'NEILL S L. Wolbachia mosquito control: tested[J]. Science, 2016, 352(6285): 526. DOI:10.1126/science.352.6285.526-a.

ZHENG X Y, ZHANG D J, LI Y J, et al . Incompatible and sterile insect techniques combined eliminate mosquitoes[J ] . Nature, 2019, 572(7767): 56-61. DOI:10.1038/s41586-019-1407-9.

SCREATON G, MONGKOLSAPAYA J. Which dengue vaccine approach is the most promising, and should we be concerned about enhanced disease after vaccination? the challenges of a dengue vaccine[J]. Cold Spring Harb Perspect Biol, 2018, 10(6): a029520. DOI:10.1101/cshperspect.a029520.

ANDERSON K B, ENDY T P, THOMAS S J. The dynamic role of dengue cross-reactive immunity: changing the approach to defining vaccine safety and efficacy[J]. Lancet Infect Dis, 2018, 18(10): e333-e338. DOI:10.1016/S1473-3099(18)30126-9.

LIU Y, LIU J Y, CHENG G. Vaccines and immunization strategies for dengue prevention[J]. Emerg Microbes Infect, 2016, 5(7): e77. DOI:10.1038/emi.2016.74.

LIU Y, ZHANG F C, LIU J Y, et al . Transmission-blocking antibodies against mosquito C-type lectins for dengue prevention[J ] . PLoS Pathog, 2014, 10(2): e1003931. DOI:10.1371/journal.ppat.1003931.

SUN J, LI M, WANG Y N, et al . Elaboration of tetravalent antibody responses against dengue viruses using a subunit vaccine comprised of a single consensus dengue envelope sequence[J ] . Vaccine, 2017, 35(46): 6308-6320. DOI:10.1016/j.vaccine.2017.09.063.

WANG R, GAO N, LI Y, et al . Cross-protection against four serotypes of dengue virus in mice conferred by a zika DNA vaccine[J ] . Front Cell Infect Microbiol, 2019, 9: 147. DOI:10.3389/fcimb.2019.00147.

YANG J, ZHANG J L, CHEN W, et al . Eliciting cross-neutralizing antibodies in mice challenged with a dengue virus envelope domain Ⅲ expressed in Escherichia coli [J ] . Can J Microbiol, 2012, 58(4): 369-380. DOI:10.1139/w11-137..

YUAN J Z, YANG J, HU Z, et al . Safe staphylococcal platform for the development of multivalent nanoscale vesicles against viral infections[J ] . Nano Lett, 2018, 18(2): 725-733. DOI:10.1021/acs.nanolett.7b03893.

PIXLEY K V, FALCK-ZEPEDA J B, GILLER K E, et al . Genome editing, gene drives, and synthetic biology: will they contribute to disease-resistant crops, and who will benefit?[J ] . Annu Rev Phytopathol, 2019, 57: 165-188. DOI:10.1146/annurev-phyto-080417-045954.

LIU T, YANG W Q, XIE Y G, et al . Construction of an efficient genomic editing system with CRISPR/Cas9 in the vector mosquito Aedes albopictus[J ] . Insect Sci, 2019, 26(6): 1045-1054. DOI:10.1111/1744-7917.12645.

SHAPIRO R S, CHAVEZ A, PORTER C B M, et al . A CRISPR-Cas9-based gene drive platform for genetic interaction analysis in Candida albicans[J ] . Nat Microbiol, 2018, 3(1): 73-82. DOI:10.1038/s41 564-017-0043-0.

浏览量

下载量

CSCD

文章被引用时，请邮件提醒。

提交

工具集

关联资源

新型冠状病毒疫苗佐剂的研究现状与展望

虫媒病防控研究与卫勤保障

HIV-1疫苗诱导与自然感染产生抗体鉴别诊断试纸研制及评价

上皮膜蛋白2多肽疫苗在鼠乳腺癌中的免疫防治效果研究

超级细菌疫苗研究进展